Insmed CFO Sara Bonstein to Depart October 30; FY26 Guidance Reaffirmed
INSM sits 25% above its 52-week low of $90.39.
Summary
Insmed announced CFO Sara Bonstein will step down on October 30, 2026, after nearly seven years, to pursue a broader leadership role. She will participate in the company's October 29 earnings call. The company reaffirmed full-year 2026 revenue guidance and expects cash flow to turn positive next year.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — Insmed expects cash flow to turn positive next year.
- Sara Bonstein will participate in the company's earnings call on Oct. 29.
- Sara Bonstein is leaving to pursue a broader leadership role.
Key Events · Executive and Board Changes · INSM
-
New · · Dow Jones Newswires
Cash Flow Positivity Expected
Insmed expects cash flow to turn positive next year.
-
Updated · · Dow Jones Newswires
CFO Departure Announced
Sara Bonstein will step down as CFO effective October 30, 2026, after nearly seven years, to pursue a broader leadership role. The company states the separation is not related to any disagreement on accounting, financial statements, internal controls, or operations.
-
Updated · · Dow Jones Newswires
Q3 Earnings Call Scheduled
Third-quarter 2026 financial results will be released on Thursday, October 29, 2026, with a conference call at 8:00 a.m. ET. Sara Bonstein will participate in the company's earnings call on Oct. 29.
-
FY26 Guidance Reaffirmed
Insmed reaffirmed full-year 2026 revenue guidance of $1.25B–$1.40B for BRINSUPRI and $450M–$470M for ARIKAYCE.
-
CFO Search Underway
Insmed has commenced a search to identify its next CFO, partnering with a leading executive search firm.
Analysis · INSM · Life Sciences
Insmed's CFO is leaving after nearly seven years, effective October 30, 2026, to pursue a broader leadership role. The company explicitly states the separation is not related to any disagreement on accounting, financial statements, internal controls, or operations — a standard disclosure that reduces the risk of a hidden financial problem. The departure comes as Insmed approaches cash flow positivity next year, with BRINSUPRI and ARIKAYCE driving revenue. The company also reaffirmed full-year 2026 guidance, signaling confidence in the commercial trajectory. The CFO transition is a governance event that warrants attention, but the reaffirmed guidance, expected cash flow positivity, and explicit no-disagreement language soften the impact.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INSM was trading at $112.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3B. The 52-week trading range was $90.39 to $212.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.